Filing Details
- Accession Number:
- 0001209191-20-065059
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-23 17:45:24
- Reporting Period:
- 2020-12-21
- Accepted Time:
- 2020-12-23 17:45:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc. | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1543031 | Daphne Quimi | C/O Amicus Therapeutics 1 Cedar Brook Drive Cranbury NJ 08512 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-12-21 | 5,000 | $2.94 | 249,344 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-12-21 | 5,000 | $24.09 | 244,344 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2020-12-21 | 5,000 | $0.00 | 5,000 | $2.94 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 16,628 | 2024-06-26 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $23.60 to $24.45. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- All of the options were fully vested and exercisable as of the transaction date.
Billionaire Hedge Funds
